Skip to main content
CRSP
NASDAQ Life Sciences

CRISPR Therapeutics Reports Reduced Q1 Loss, Strong Cash Position, and Broad Pipeline Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$53.039
Mkt Cap
$5.167B
52W Low
$33.03
52W High
$78.48
52W Position info
61% above low
Off High info
32% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CRSP sits 61% above its 52-week low of $33.03.

Summary

CRISPR Therapeutics reported a reduced net loss and a substantial increase in cash, driven by convertible notes, alongside initial CASGEVY revenue and broad advancements across its clinical pipeline.


Key Events · Earnings and Guidance · CRSP

  • Reduced Net Loss

    Q1 2026 net loss decreased to $122.9 million, down from $136.0 million in Q1 2025.

  • Strengthened Cash Position

    Cash, cash equivalents, and marketable securities increased to $2.44 billion as of March 31, 2026, primarily due to $585.4 million in net proceeds from convertible senior notes issued in March 2026.

  • Initial CASGEVY Revenue

    Generated $43 million in revenue from CASGEVY in Q1 2026, with over 500 patients globally initiating the treatment journey.

  • Broad Pipeline Advancement

    Multiple clinical programs, including CTX310, CTX460, CTX340, CTX611, and zugo-cel, are progressing, with new IND clearances and positive early data for zugo-cel in autoimmune diseases.


Analysis · CRSP · Life Sciences

CRISPR Therapeutics AG reported a reduced net loss for Q1 2026 and significantly strengthened its liquidity with a $585.4 million cash increase from convertible senior notes, extending its cash runway. The company also announced initial commercial revenue of $43 million for CASGEVY and provided extensive updates on its diverse clinical pipeline, including new IND clearances and positive early data for zugo-cel in autoimmune diseases. These developments highlight strong operational execution and significant progress across its gene-editing platforms.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRSP was trading at $53.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $33.03 to $78.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRSP - Latest Insights

CRSP
Nov 10, 2026, 1:48 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $45.48
Real-time Price: $39.50 info
Change: -$5.98 (-13%) info
Market Cap: $3.793B info
CRSP
Nov 09, 2026, 9:16 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $50.42
Real-time Price: $39.50 info
Change: -$10.92 (-22%) info
Market Cap: $3.793B info
CRSP
Nov 02, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $49.98
Real-time Price: $39.50 info
Change: -$10.48 (-21%) info
Market Cap: $3.793B info
CRSP
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $39.50 info
Change: -$9.51 (-19%) info
Market Cap: $3.793B info
CRSP
Nov 02, 2026, 4:06 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $39.50 info
Change: -$9.51 (-19%) info
Market Cap: $3.793B info